Kexing Biopharm Co., Ltd. (SHA:688136)

China flag China · Delayed Price · Currency is CNY
25.89
-2.75 (-9.60%)
Apr 29, 2026, 3:00 PM CST
-32.28%
Market Cap 5.13B
Revenue (ttm) 1.46B
Net Income (ttm) 112.05M
Shares Out 198.11M
EPS (ttm) 0.57
PE Ratio 45.65
Forward PE n/a
Dividend 0.08 (0.28%)
Ex-Dividend Date n/a
Volume 9,911,011
Average Volume 6,792,412
Open 26.00
Previous Close 28.64
Day's Range 24.07 - 26.40
52-Week Range 24.07 - 63.99
Beta 0.68
RSI 32.06
Earnings Date Apr 22, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 971
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688136
Full Company Profile

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.53 billion, an increase of 9.03% compared to the previous year's 1.41 billion. Earnings were 155.57 million, an increase of 394.17%.

Financial Statements

News

There is no news available yet.